$34.400
-0.409 (-1.19%)收盘时
COAG 同业对比
In the context of the broader market, COAG competes directly with industry leaders such as KMDA and ABSI. With a market capitalization of $1.60B, it holds a significant position in the sector. When comparing efficiency, COAG's gross margin of N/A stands against KMDA's 40.91% and ABSI's 100.00%. Such benchmarking helps identify whether Hemab Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.
Hemab Therapeutics Holdings Inc 财务表现
Hemab has reported substantial net losses, with Q2 2026 net income at -24,150,000 USD and an EPS of -0.52, indicating ongoing financial challenges despite the potential for future growth.
Financials
FY2026Q2
YoY:
+62.42%
-26.08M
Operating Profit
FY2026Q2
YoY:
+97.80%
-24.15M
Net Income after Tax
FY2026Q2
YoY:
+85.71%
-0.52
EPS - Diluted
FY2026Q2
YoY:
+47.79%
-22.66M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。